Exelixis Wins Patent Ruling Over MSN Labs’ Cabometyx Copies

A federal judge in Delaware upheld the validity of three patents for Exelixis Inc.’s Cabometyx that MSN Laboratories Private Ltd. had conceded its generic version of the blockbuster cancer drug infringes, blocking the copies until the patents’ January 2030 expiration.

Judge Richard G. Andrews also found MSN’s generic doesn’t infringe US Patent No. 11,298,349, though he rejected arguments for invalidating the patent, according to an opinion issued Tuesday in the US District Court for the District of Delaware. The ’349 patent expires in February 2032, according to the US Food and Drug Administration’s registry of approved drugs, the Orange ...